CorWave announced today that chronic in vivo studies of its implantable heart pump have proven “unprecedented” with strong results.
Presenting at the annual meeting for the International Society for Heart and Lung Transplantation (ISHLT), CorWave touted the study as the first ever to demonstrate sensorless synchronization of a pericardial pump with the native heart for over 30 days, according to a news release.
Clichy, France’s implantable left ventricular assist device (LVAD), which uses its breakthrough wave membrane pump technology, is designed to offer a wide range of flow conditions, gentle blood propulsion and to generate physiologic pulsatility in an effort to reduce the adverse events associated with current LVAD technologies.
Study results from the trials in which the CorWave device operated in pulsatile mode by synchronizing with the native heart without the aid of sensors demonstrated more than 97% success in detecting heartb…